India’s LSD Rare Disease Biobank has marked a historic moment in the country’s health and research landscape. For the first time, a government-supported national biobank has been created to focus exclusively on Lysosomal Storage Disorders (LSDs), a group of rare and life-threatening genetic conditions. This initiative brings together researchers, doctors, and institutions from across the country with a shared aim: to improve diagnosis, research, and treatment options for thousands of affected families.

Thank you for reading this post, don't forget to subscribe!

India’s LSD Rare Disease Biobank and Its National Significance

India’s LSD Rare Disease Biobank has been established through the combined efforts of researchers from 28 medical and research institutions spanning six states and two Union Territories. The biobank integrates biological samples with detailed clinical, biochemical, and genetic information from 530 patients belonging to 15 different states. This wide representation makes it one of the most comprehensive rare disease resources ever developed in the country.

The project is funded by the Department of Biotechnology under the Government of India, reflecting strong public support for rare disease research. By creating a centralised and well-curated repository, the biobank fills a long-standing gap in India’s healthcare system, where rare disease data was previously scattered and limited.

Understanding Lysosomal Storage Disorders in India

Lysosomal Storage Disorders are inherited metabolic diseases caused by the absence or malfunction of specific enzymes. These enzymes normally break down fats, sugars, or other complex molecules inside cells. When they do not function properly, harmful substances build up within cells and tissues, leading to progressive damage to organs such as the brain, liver, heart, and bones.

Globally, more than 70 different LSDs have been identified. In India, it is estimated that over 12,000 people live with some form of LSD. Many of these patients are children who develop symptoms early in life. Without timely diagnosis and treatment, the disease often progresses rapidly.

One of the most troubling realities is the high cost of treatment. Available therapies, mainly enzyme replacement treatments, can cost more than Rs 1 crore per patient each year. Because of this, only a very small number of patients can access treatment. Among the 530 patients documented in the biobank, nearly 60 percent have already died, and only eight are currently receiving therapy.

Leadership and Scientific Foundation of the Biobank

India’s LSD Rare Disease Biobank is led by the Foundation for Research in Genetics and Endocrinology and the Institute of Human Genetics in Ahmedabad. Their leadership has ensured that the project follows strict scientific and ethical standards.

The work related to the biobank has been published in the Orphanet Journal of Rare Diseases, giving it international visibility and credibility. The biobank currently covers eight major LSD subgroups across 27 specific disorders, making it a rich resource for both national and global researchers.

What the Biobank Contains

The strength of India’s LSD Rare Disease Biobank lies in the depth and quality of its data. Biological samples collected include genomic DNA extracted from blood, plasma, and urine precipitates. These samples are carefully processed and preserved for enzyme testing and genetic analysis.

Among the recorded conditions, Gaucher disease appears most frequently with 70 cases, followed by Tay-Sachs disease with 62 cases. Other commonly documented disorders include Mucolipidosis II and III with 44 cases and Morquio-A syndrome with 40 cases. Each sample is linked to detailed patient histories, clinical findings, and laboratory results, allowing researchers to study disease patterns more effectively.

Digital Platform and Data Integration

A key feature of India’s LSD Rare Disease Biobank is its centralised digital platform. This system securely stores clinical and genomic data and allows authorised researchers to access information for approved studies. Such integration ensures that data is not only preserved but also actively used.

This digital approach reduces duplication of effort and helps scientists identify trends, genetic variations, and potential targets for therapy. It also supports collaboration across institutions, making research faster and more efficient.

Research Collaborations and Innovation

The biobank is already playing an active role in advancing research. One major collaboration is with the Tata Institute for Genetics and Society in Bengaluru, where scientists are developing human stem cell-based disease models. These models allow researchers to study how LSDs affect cells and to test possible treatments in a controlled environment.

At the same time, the Institute for Stem Cell Science and Regenerative Medicine is working on broader therapeutic strategies that could be applied to multiple LSDs. Another important partner, the Centre for DNA Fingerprinting and Diagnostics, is developing spectrometry-based screening technologies. These tools could help detect LSDs earlier, even before severe symptoms appear.

Impact on Families and the Healthcare System

For families affected by rare diseases, India’s LSD Rare Disease Biobank offers hope. Early diagnosis can significantly improve quality of life and, in some cases, extend survival. With better data and research support, doctors may be able to identify LSDs sooner and guide families toward appropriate care.

From a broader perspective, the biobank strengthens India’s healthcare system by supporting indigenous research and reducing dependence on imported technologies. Over time, this could lead to more affordable diagnostic tools and therapies developed within the country.

A Strong Foundation for the Future

India’s LSD Rare Disease Biobank represents a turning point in how rare diseases are approached in the country. By bringing together data, samples, and expertise under one national framework, it creates a strong foundation for future discoveries. The initiative not only advances science but also reflects a commitment to some of the most vulnerable patients in society.

As research continues and collaborations grow, the biobank is expected to play a crucial role in shaping policies, guiding investment, and improving outcomes for children and families living with Lysosomal Storage Disorders.